Press Release | Propel Bio Partners Highlights Leen Kawas’s Vision for a New Generation of Biotech Founders

Leen Kawas has built her investment philosophy at Propel Bio Partners around a simple premise: most biotech startups don't fail because the science is wrong. They fail because founders underestimate how much operational discipline, hiring strategy, and commercialization planning matter alongside the research. The firm's latest press release breaks down how that founder-first approach is shaping their portfolio strategy across diagnostics, therapeutics, precision medicine, and digital health.

Read the Full Article Here